Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal V

NCT01229397 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
205
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Crucell Holland BV